The introduction of synthetic nicotine alternatives like 6-methyl nicotine in vapes is raising concerns due to their potential higher potency and addictive nature compared to traditional nicotine. The FDA and researchers are investigating these compounds, but current data is insufficient. Regulatory gaps allow these products to be marketed without FDA authorization, posing risks to consumers.
New Compounds Boost Battle Against Tuberculosis, Depression miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Novel compounds show promise in the fight against tuberculosis and neurodegenerative disease phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of.
The Kentucky Network for Innovation and Commercialization funded nine proof-of-concept projects in Cycle 5 to researchers at UK, UofL, EKU, NKU and WKU.